Antliabio 310
Alternative Names: Antliabio-310Latest Information Update: 26 Apr 2023
At a glance
- Originator Antlia Bioscience
- Class Cardiovascular therapies; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cardiovascular disorders
Most Recent Events
- 10 Apr 2023 Preclinical trials in Cardiovascular disorders in USA (Parenteral), prior to April 2023 (Antlia Bioscience pipeline, April 2023).